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S U M M A R Y
Rapid diagnostics, newer drugs, repurposed medica-
tions, and shorter regimens have radically altered the
landscape for treating rifampicin-resistant TB (RR-TB)
and multidrug-resistant TB (MDR-TB). There are
multiple ongoing clinical trials aiming to build a robust
evidence base to guide RR/MDR-TB treatment, and
both observational studies and programmatic data have
contributed to advancing the treatment field. In Decem-
ber 2019, the WHO issued their second ‘Rapid
Communication’ related to RR-TB management. This
reiterated their prior recommendation that a majority of
people with RR/MDR-TB receive all-oral treatment
regimens, and now allow for specific shorter duration
regimens to be used programmatically as well. Many TB
programs need clinical advice as they seek to roll out
such regimens in their specific setting. In this Perspective,
we highlight our early experiences and lessons learned
from working with National TB Programs, adult and
pediatric clinicians and civil society, in optimizing
treatment of RR/MDR-TB, using shorter, highly-effec-
tive, oral regimens for the majority of people with RR/
MDR-TB.
K E Y W O R D S : TB; drug-resistant; oral regimen; MDR-
TB; human rights
RIFAMPICIN-RESISTANT TB (RR-TB) and multi-
drug-resistant TB (MDR-TB) are significant global
health problems. Unless far-reaching and urgent
action is taken, they will be responsible for one out
of every four global deaths caused by antimicrobial
resistance by 2050.1 An estimated 484 000 people
develop RR-TB/MDR-TB each year, and of the
156 071 (32.2%) people who receive treatment
annually, fewer than 60% are cured.2 Such poor
outcomes are due in part to the use of long (i.e., 18–
24 month) regimens with highly toxic medications,
most of which have not been assessed in clinical
trials3 and which are administered with only limited
patient support.4
However, there is cause for optimism, with the
introduction of newer medications, repurposed
agents, and shorter therapeutic options for the
treatment of RR/MDR-TB based on clinical trials,
observational studies and data from TB programs.5–8
The 2019 WHO consolidated guidelines offered three
possible therapeutic options for countries and pro-
grams treating people with RR/MDR-TB: an all-oral
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longer (18–20 month) regimen; an injectable-con-
taining shorter (9–12 month) regimen; and an all-oral
shorter (9–12 month) regimen implemented under
operational research conditions. However, country
programs and their implementing partners were
unclear about which regimens to prioritize. Delays
in releasing an updated version of the Companion
Handbook for Programmatic Management of RR/
MDR-TB further compounded the situation.9
In November of 2019, the WHO once again
convened an RR/MDR-TB guideline development
group to assess additional evidence on several specific
clinical topics.10 These included: 1) the use of all-oral
shorter regimens for RR/MDR-TB; 2) the use of the
three-drug, 6-month, ‘Nix-TB’, BPaL regimen; and 3)
the use of bedaquiline (BDQ) and delamanid (DLM)
in combination or when given for durations longer
than 6 months. The group reviewed the evidence from
South Africa, where over 4000 individuals were
treated with a modified, all-oral shorter regimen
consisting of the 2016 standardized regimen with
BDQ replacing the injectable (mostly due to baseline
hearing loss, baseline renal failure, or the develop-
ment of injectable toxicity during treatment). In
December 2019, the WHO then issued a statement
supporting the use of all-oral shorter, BDQ-contain-
ing regimens.* The WHO also conditionally recom-
mended the use of an all-oral shorter regimen
containing BDQ, higher-dose linezolid (LZD) (1200
mg daily), and the novel nitroimidazole pretomanid
(PTM) (the ‘BPaL regimen’) under operational
research conditions for people with fluoroquinolone
(FQ) resistant TB/treatment intolerant RR/MDR-TB.
As countries struggle to rapidly transition to all-
oral regimens, they need clinical guidance and
support to optimize the use of shorter, highly-
effective, oral regimens for RR/MDR-TB (‘SHORRT’
therapy) and the BPaL regimen. Note the term ‘highly
effective’ is based on limited data compared to 2016
WHO recommended longer regimen: it is acknowl-
edged that more data is needed to confirm effective-
ness. Such guidance is not yet available globally,11
and some groups are still erroneously recommending
an injectable-containing, shorter regimen for RR/
MDR-TB treatment, despite the highly toxic nature
of injectable medications.12 As clinicians, implement-
ing partners, and program managers with early
implementation experiences, we are using this Per-
spective article to provide evidence-based recommen-
dations.
METHODS
The clinical practice principles in this Perspective are
based on field experience of providing direct care for
people with RR/MDR-TB, engaging with TB pro-
grams, and listening to the views of TB-affected
communities and civil society. Collectively, the
authors have more than five decades experience
working on RR/MDR-TB, and have worked exten-
sively in the field since newer drugs and shorter
regimens became available, supporting more than 30
countries during this time period. In addition to our
robust, direct field experience, several of us have
provided evidence for and served as observers and
voting members at the 2016, 2018, and 2019 WHO
Guideline Development Group Meetings. To ensure
our coverage was comprehensive, we carried out a
literature review using OVID, MedLINE and
PubMED databases from January 1, 2016 to Febru-
ary 1, 2020 using the terms: ‘rifampicin-resistant
tuberculosis’ or ‘drug-resistant tuberculosis’ with
‘bedaquiline’, ‘delamanid’, ‘shorter’, ‘World Health
Organization’ or ‘operational research’. Because
there are only limited published data on the use of
newer drugs and shorter regimens, expert consensus
from the authors was reached if evidence was lacking.
The development process differed from that used by
some normative bodies (such as the WHO) as it
considered practice-based experience in addition to
those described in the published literature. For the
sake of clarity, we have noted in the text when the
perspectives are based on the published evidence and
when they are based on the opinion of the authors.
CLINICAL PERSPECTIVES
Eliminating the injectables
In 2019, the WHO and its Civil Society Task Force
announced they ‘strongly recommend that all coun-
tries transition to an all-oral regimen for drug-
resistant TB by World TB Day 2020.’13 The 2018
WHO guidelines and the 2019 Rapid Communica-
tion provide a framework for doing so for the
majority of patients (except for those requiring
‘salvage’ regimens). Countries must move swiftly to
ensure that injectables are no longer routinely used
for the treatment of RR/MDR-TB, because there is
only limited evidence of their efficacy and extensive
examples of their toxicity.14 Continued use of these
injectables when safer, more effective treatments are
available violates both Good Clinical Practice and the
human rights of people with RR/MDR-TB. Under no
conditions should kanamycin or capreomycin be
used. Although there may be some people with RR/
MDR-TB whose strains are highly resistant, or who
have received multiple unsuccessful treatment regi-
mens in the past who require amikacin (AMK)
therapy (usually as part of ‘salvage’ or ‘rescue
* These recommendations were confirmed in the 2020 WHO
Guidelines for the treatment of RR/MDR-TB and the updated
Companion Handbook, both of which were released in June of
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regimen’), AMK should only be used in people with
no other treatment options, and should be accompa-
nied by baseline and routine monitoring for hearing
loss. It is the opinion of the authors that countries
should not continue using injectables to ‘finish their
stocks’, and major donors (including the Global Fund
for AIDS, Tuberculosis and Malaria and USAID)
must support immediate transition to all-oral regi-
mens. AMK can be used to treat other serious gram-
negative bacterial infections and could be donated to
other disease programs in country if needed. It is the
opinion of the authors that programs should monitor
and report the number of people started on injectable-
containing regimens as a basic quality of care
indicator. Formal monitoring for adverse drug
reactions associated with injectables (hearing loss,
renal failure) is required when AMK is used. Of note,
although the term ‘injectable’ as used in this article
refers to the aminoglycosides and capreomycin, there
has been increased documentation of the successful
use of carbapenems in combination with clavulanic
acid as part treatment regimens for RR/MDR-TB.15
These drugs must be administered intravenously (or
intramuscularly in the case of ertapenem) and given
the limited evidence on their efficacy, the authors
suggest they only be administered in longer regimens
for patients with limited treatment options.
Duration of therapy
The WHO has recommended an all-oral shorter (9–
12 month) regimen for people with RR/MDR-TB
who do not have known or likely FQ resistance;
severe forms of disease; or other exclusion criteria
(see Figure). An all-oral longer (18–20 month)
regimen is recommended for people with RR/MDR-
TB who have documented or likely FQ resistance,
severe forms of disease, or meet other criteria that
make them otherwise ineligible to receive a shorter
regimen (see Figure). Consequently, all people diag-
nosed with RR/MDR-TB need to undergo rapid
testing for FQ resistance, using a line-probe assay.
Other tests may be available in the future, including
the expanded Xpertw MTB/RIF cartridge (Cepheid,
Sunnyvale, CA, USA),16 which can also detect
resistance to isoniazid (INH), the FQs, and the
injectable agents. If FQ susceptibility is not con-
firmed, people with risk factors for FQ resistance—
including those with a prior history of RR/MDR-TB
treatment, exposure to a known contact with FQ
resistance, or residence in a region where FQ
resistance is high (although there is currently no clear
Figure Algorithm for all-oral treatment for RR-TB. FQ ¼ fluoroquinolone; RR-TB ¼ rifampin-
resistant tuberculosis; SHORRT¼shorter, highly-effective, oral regimens for RR/MDR-TB therapy;
OR¼ operational research.
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guidance on what is considered to be ‘high’)—should
receive a longer, all-oral regimen.
Some countries are using other criteria to decide
who can receive a shorter, all-oral regimen. Because
molecular methods may miss some cases where FQ
resistance is present, people with documented inject-
able resistance or with both inhA and katG INH
resistance mutations could be considered for longer
regimens. The especially applies if the shorter regimen
contains INH or ethionamide (ETH)—unless FQ
susceptibility can be documented. This is because the
presence of both these INH mutations in M. tubercu-
losis strains may be a marker for FQ resistance.17
Pregnant and breastfeeding women, people with HIV,
people with underlying liver disease, people who are
incarcerated, people who are migrants/refugees/asylum
seekers, and other vulnerable populations are all eligible
to receive shorter regimens. Children are a population
who should be prioritized for shorter regimens, but the
duration of therapy in the pediatric population should
be determined by the extent of disease.18
Regimen design: ‘SHORRT’ therapy
The 2019 WHO Rapid Communication recommends
giving the 2016 WHO-recommended regimen but
replacing the injectable agent with BDQ. Thus, the
recommended regimen (the number of months the
drug is administered in parentheses) is: BDQ
(6)þETH (4–6)þhigh-dose INH (4–6)þlevofloxacin
(LVX) (9)þclofazimine (CFZ) (9)þpyrazinamide
(PZA) (9)þethambutol (EMB) (9). Because the
regimen has numerous limitations, concerns have
been raised about its use. First, the regimen contains
seven drugs and is a substantial pill burden for people
with the disease. Second, the regimen contains EMB
and PZA for which no routine drug susceptibility
testing (DST) is available in most settings: also these
drugs may be of limited utility given the high rates of
resistance seen among the M. tuberculosis strains of
people with RR/MDR-TB and prior use of these two
agents.19 Third, the regimen continues to utilize ETH,
a drug with multiple adverse drug reactions, which
can lead to treatment intolerance, especially nausea
and vomiting. Furthermore, in the meta-analysis that
informed the 2018 WHO recommendations, ETH
use was associated with worse treatment outcomes,
even among people whose strains were susceptible to
the drug, leading to a conditional recommendation
for the medication to only be used in ‘salvage’ or
‘rescue’ regimens.20 Fourth, a simple BDQ substitu-
tion in the 2016 shorter regimen means that people
will not be treated with all three group A drugs—
drugs that have been associated with improved
treatment outcomes and lower mortality rates—since
LZD is not included in the regimen. Fifth, there are
concerns that in settings where FQ resistance is
common, a simple BDQ substitution could amplify
resistance, especially since results for FQ DST may be
delayed for weeks to months (notably with people
with smear-negative RR/MDR-TB). This concern is
amplified in settings where there is limited experience
performing and interpreting line-probe assay (LPA)
results. Finally, there has been inconsistent experience
with the dose and selection of the FQs used in the
injectable containing shorter regimens, with some
studies using moxifloxacin (MFX) at ‘high doses’ and
some at standard doses.21 Of note, the regimen
reviewed by the Guideline Development Group in
2019 utilized LVX at a dose of 15–20 mg/kg/day.
There are several alternative all-oral shorter
regimens being used globally, and it is the opinion
of the authors that countries should consider coun-
trywide implementation of an all-oral regimen
suitable to their local context. It is likely the WHO
will review data from these regimens in the next 12 to
18 months, and there is regional and country-wide
experience using the regimens described below:
1) The 2016 shorter regimen in which the injectable
is replaced by BDQ and ETH is replaced by LZD, at
least until results from FQ resistance testing are
available. This regimen includes all three Group A
drugs and is first-line therapy for all people living
with RR/MDR-TB in South Africa, where it has been
given to thousands of individuals under enhanced
monitoring implementation conditions. Its limita-
tions include the continued use of PZA, EMB, and
INH which have unclear efficacy in the context of
treatment for RR/MDR-TB, increase the pill burden
and are associated with adverse events. The combined
use of INH and LZD—both of which can cause
peripheral neuropathy—is especially problematic,
most notably in other populations with risk factors
for neuropathy, including people living with diabetes,
people who use alcohol, and people living with HIV,
although this risk could be mitigated by using LZD
for a shorter duration (i.e., 8 weeks or less).
2) One of the ‘endTB’ regimens. The endTB project is
funded by Unitaid and carried out by the humanitarian
organizations Interactive Research & Development,
Médecins Sans Frontières, and Partners In Health. It has
an observational study component22 and two random-
ized clinical trials: endTB (NCT02754765) and endTB-
Q (NCT03896685). The observational cohort data—
which included people who received newer drugs (BDQ
and/or DLM), people who received repurposed drugs,
and some people who received ‘salvage’ regimens that
included injectable agents—were presented at the 50th
Union World Conference on Lung Health. The
treatment success was 77.6% among people receiving
newer drugs and 84.8% in the subset of patients who
received all-oral regimens (n¼ 259).23 The endTB trial
is assessing several different regimens for patients with
RR/MDR-TB and confirmed FQ susceptibility, each
lasting 9 months and containing different combinations
of the drugs BDQ, LZD, LVX/MFX, DLM, CFZ, and/
or PZA. Two of the regimens are being used in program
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settings. The first contains BDQ, LZD, LVX, CFZ and
PZA. This regimen uses all three group A drugs as well
as one of the group B drugs plus PZA. The second
regimen being used programmatically consists of BDQ,
LZD, DLM, LVX, and PZA. This regimen contains all
three group A drugs as well as PZA and DLM. Results
from the endTB trial are expected in 2022. The endTB-
Q study has recently begun enrolling and uses a regimen
of BDQ, DLM, LZD and CFZ for people with FQ-
resistant RR/MDR-TB.
3) A novel regimen lasting 9–12 months consisting
of the five group A and B drugs: BDQ, LZD, LVX,
CFZ, and cycloserine: this regimen is being assessed
under operational research conditions in some
settings (i.e., Ukraine, the Philippines). The rationale
for using this regimen is that it uses all the drugs
recommended by the WHO for treatment of RR/
MDR-TB that have been associated with improved
treatment outcomes. Some programs are also consid-
ering the use of a 9–12-month regimen which adds
DLM to the group A and B drugs above, but there has
been limited implementation experience with this
regimen and it is unclear why six drugs would be
needed at treatment initiation.
In each of these examples, LVX is used instead of
MFX because the regimens contain at least two other
medications that prolong the corrected QT interval
calculated using the Fridericia formula (QTcF inter-
val) (BDQ and CFZ or DLM) and LVX has fewer
effects on the QTcF interval. Of note, these regimens
may also utilize BDQ for the entire duration of
therapy, as published studies and the 2019 WHO
review did not identify any increase in adverse drug
reactions when BDQ is given beyond 24 weeks.
Except for the endTB-Q study, these regimens are
only recommended for people in whom FQ resistance
has been ruled out or is unlikely (i.e. no previous FQ
exposure for .1 month, no exposure to a person with
known FQ resistance, no other risk factors for FQ
resistance as described in the Figure). The duration of
therapy is usually 9–12 months and dependent in
some regimens on the smear status at month 4 or on
the completion of a certain number of doses. While
there is a theoretical concern for continued exposure
to BDQ after treatment completion give its long half-
life, the clinical implications of this are unclear.
The authors’ clinical opinions on SHORRT thera-
py are summarized in Tables 1, 2 and 3. Table 1
compares the advantages and disadvantages for each
of these regimens. Clinical perspectives on monitor-
ing for and managing adverse drugs reactions are
included in Table 2. Considerations for special
populations are included in Table 3.
Regimen design: longer regimens and fluoroquinolone
resistance
If FQ resistance is documented or likely, then the
patient does not qualify for SHORRT therapy and
will likely need to be treated with a longer, all-oral
regimen lasting 18 to 20 months. The principles of
regimen construction for such individuals should
follow the WHO groupings and the regimens should
include at least five drugs. In practice, regimens for
people with FQ-resistant RR/MDR-TB almost al-
ways contain DLM, since this drug appears to be safe
and has shown effectiveness in the treatment of RR/
MDR-TB. All efforts should be made to avoid
injectables in the longer regimens if equally effective
and safer alternatives are available. For a subset of
patients, however, a carbapenem such as meropenem
or imipenem in combination with clavulanic acid
(available only as amoxicillin-clavulanate) or AMK
(if there is susceptibility to this drug and formal
audiological assessments are available) may be
needed to construct a regimen with enough effective
drugs. Data on the safety of BDQ and DLM use in
combination, both from observational cohorts24–27
and from a randomized controlled trial,28 has shown
that giving these two drugs together does not lead to an
excess increase in QTcF prolongation. The 24-week
administration period for both BDQ and DLM was
selected so clinical trials could be completed in a
shorter time period, not because of any evidence of
cumulative toxicity or risk if either drug is adminis-
tered for longer than 24 weeks.29 It is the opinion of
the authors that patients on longer regimens will likely
also need DLM and/or BDQ extended for the entire
duration of therapy, a clinical practice that is
supported by observational cohort studies, which
show no increase in adverse events with prolonged
administration.30 Policy makers and programs need to
budget for such prolongation and work to define an
oversight mechanism by which such extensions can be
supported in their local settings. Monitoring for
adverse events is essential when BDQ and/or DLM
are given for longer than 24 weeks to continue to build
the database on the safety and efficacy of this practice.
Some countries may consider using the BPaL
regimen under operational research conditions (see
section on principles for operational research) for
certain patients with FQ-resistant RR/MDR-TB and
among those for whom designing an effective regimen
based on existing WHO recommendations is not
possible. As noted above, the BPaL regimen consisting
of 6–9 months of BDQ, higher-dose LZD (1200 mg
daily) and the novel nitroimidazole PTM was recently
approved under the ‘Limited Population Pathway for
Antibacterial and Antifungal Agents’ by the FDA.31
This is a new regulatory approval pathway that is
intended for treatment of diseases associated with high
mortality and for which limited therapeutic options
exist. The evidence required for approval using this
mechanism is less rigorous than for medication
approved through other FDA pathways.32 The FDA
did not grant approval to any of the single agents in the
BPaL regimen and only recommended the entire
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regimen for people with extensively drug-resistant TB
(XDR-TB—RR/MDR-TB with resistance to both an
injectable and a FQ), pre-XDR-TB (i.e., RR/MDR-TB
with resistance to either a FQ or injectable), or
treatment intolerant/non-responsive RR/MDR-TB.
This regimen should not be given to people who have
been previously treated with two or more weeks of
BDQ, LZD, or DLM (given the possibility of cross-
resistance between DLM and PTM), unless there is
DST documenting susceptibility to these agents. In


















Optic neuritis/neuropathy LZD, EMB Monthly clinical assessment
with standardized visual
acuity and color vision
testing
Snellen chart, Ishihara color
plates
Prednisone may be




QTcF prolongation BDQ, CFZ, MFX,
DLM, LVX










of note, any drug
can cause
hepatotoxicity





TB medications that can
be used in liver-
sparing regimens
Skin hyperpigmentation CFZ Ongoing counseling and
support, especially around
inadvertent disclosure
Use of sunscreen or
avoidance of direct
sunlight
* Mehta S, et al. Implementation of a validated peripheral neuropathy screening tool in patients receiving antiretroviral therapy in Mombasa, Kenya. Am J Trop
Med Hyg 2010; 83(3): 565–570.
RR/MDR-TB¼ rifampin-resistant/multidrug-resistant tuberculosis; LZD¼ linezolid; HD-INH¼high-dose isoniazid; CS¼cycloserine; EMB¼ethambutol; BDQ¼bedaquiline;
CFZ¼ clofazimine; MFX¼moxifloxacin; DLM¼ delamanid; LVX¼ levofloxacin; ECG¼ electrocardiogram; TSH¼ thyroid stimulation hormone; PZA¼ pyrazinamide.
Table 3 Considerations for vulnerable populations
Population Special considerations
People living with HIV Cannot use BDQ with efavirenz as efavirenz lowers BDQ concentrations;
Dolutegravir-based regimens preferred;
Monitor for overlapping toxicities (i.e., linezolid/zidovudine)
Children BDQ recommended in children ages 6 years and above;
Delamanid recommended in children ages 3 years and above;
Children under these age cut-offs should be considered on a patient-by-patient basis;
Child-friendly formulations should be used;
Must be included in operational research so data can be obtained
Adolescents (10–19 years) No physiological reason to exclude them from early trials or from receiving SHORRTor
other shorter regimens;
May need additional support for diagnosis and adherence
Pregnant and breastfeeding women Limited experience with most second-line drugs in this population;
Robust regimens most likely to result in treatment success;
Must be included in operational research so data can be obtained
Hepatitis B or C Should receive treatment for viral hepatitis as part of RR/MDR-TB therapy;
May wish to avoid PZA- and INH-containing regimens
People who use alcohol or other substances Counseling and harm reduction should be offered as an essential part of treatment;
Abstinence is not required for RR/MDR-TB treatment;
May wish to avoid PZA- and INH-containing regimens
Incarcerated individuals Must be included in operational research as part of equity and human rights approach
to RR/MDR-TB;
May be more likely to benefit from shorter regimens;
Transition to civilian sector is a vulnerable time during which additional support is needed.
Migrants/refugees/asylum seekers Must be included in operational research as part of equity and human rights approach
to RR/MDR-TB;
May be more likely to benefit from shorter regimens
BDQ¼ bedaquiline; SHORRT¼shorter, highly-effective, oral regimens for RR/MDR-TB therapy; RR/MDR-TB¼ rifampin-resistant/multidrug-resistant tuberculosis;
PZA¼ pyrazinamide; INH¼ isoniazid.
1140 The International Journal of Tuberculosis and Lung Disease
people with a history of having received CFZ, BDQ
susceptibility should be confirmed as there can be
cross-resistance between BDQ and CFZ.33
Given the very limited experience with the BPaL
regimen and the need to collect additional data, it is
the opinion of the authors that patients on this
regimen be monitored closely during treatment and
for at least 24 months after treatment. Furthermore,
given the adverse events seen with PTM in other
controlled trials (especially hepatotoxicity34,35) and
the limited clinical evidence of PTM’s independent
contributions towards the efficacy of the BPaL
regimen, it should be rolled out to the populations
specified by the FDA. It is the opinion of the authors
that the BPaL regimen should not be considered for
broader use among populations with RR/MDR-TB
until additional evidence is generated, especially since
there are multiple treatment options that now exist
for individuals with all forms of RR/MDR-TB.
Clinicians treating people under the Nix-TB protocol
had significant leeway in the management of individuals
on the regimen, including those who developed toxicity
to one or more of the three medications. As per the FDA
approved package insert for PTM,36 it is strongly
recommended that all people on the BPaL regimen have
routine (i.e. monthly) and systematic screening for
peripheral neuropathy (using standard assessment tools
and grading systems), optic neuritis, liver toxicity and
bone marrow suppression. LZD-related toxicity devel-
oped in a high proportion of people who received the
BPaL regimen, and some patients required the initiation
of chronic medical therapy to manage adverse events,
most notably those with peripheral neuropathy. In some
instances of toxicity, the LZD was held and then
reintroduced at a lower dose (either 300mg or 600mg
daily). In other instances, LZD was completely
discontinued (usually after 2 months) and the remainder
of the regimen completed with just two drugs—BDQ
and PTM. If either BDQ or PTM needs to be
discontinued, however, the patient should be transi-
tioned to a ‘salvage’ or ‘rescue’ regimen in some
instances. The ongoing ‘Ze-Nix’ trial (NCT03086486)
will assess different doses of LZD to see if lower rates of
adverse drug reactions can be achieved.37 Results of this
study are expected in 2020.
It is the opinion of the authors that countries may
also consider using DLM as the nitroimidazole of
choice in a BDQ and LZD-containing regimen (as is
being done in the endTB study, the endTB-Q study,
the BEAT TB study in South Africa, NCT04062201
and the SMART KIDS IMPAACT 2020 study);
however, there have been no head-to-head compari-
sons of DLM and PTM to assess the comparative
efficacy and safety of these two nitroimidazoles,
including in the context of the BPaL regimen. DLM
has an excellent safety profile and can be given to
children; however, in a phase III randomized,
placebo-controlled trial, DLM failed to reach its
primary efficacy endpoint.38 It is the opinion of the
authors that a trial comparing these two nitro-
imidazoles is a priority in RR/MDR-TB clinical
research. Countries may also consider using the
regimens being assessed in the Unitaid-sponsored
‘endTB-Q’ study as SHORRT regimen options for
people whose M. tuberculosis strains have known or
possible FQ resistance. This regimen consists of BDQ,
DLM, LZD and CFZ given daily for 9–11 months.39
Principles for operational research and programmatic
considerations
WHO recommendations on the treatment of RR/
MDR-TB over the past several years have routinely
recommended novel treatment regimens, including
SHORRTregimens, be implemented under ‘operational
research conditions.’ Table 4 reviews the authors’
opinions regarding important considerations for oper-
ational research on RR/MDR-TB. The authors’ opin-
Table 4 Operational research considerations for all-oral
treatment of RR/MDR-TB
1 Operational research is usually recommended when there is
clinical rationale or emerging evidence favoring the use of a
drug or regimen, but the WHO has not been able to formally
assess select regimens due to insufficient data for review
2 Operational research is not meant to replicate or replace clinical
trials but rather to help countries answer questions about
optimal implementation in the populations they are treating in
everyday practice
3 Operational research should focus on the populations of people
with RR/MDR-TB who receive care within national programs: as
such, children, pregnant women, breastfeeding women,
people who are incarcerated, migrants/refugees/asylum
seekers, and people who use/abuse substances (including
alcohol) should be included
4 While there are multiple, ongoing clinical trials of SHORRT
therapy,* there is also a need to collect and analyze data on the
implementation of and how such regimens perform under field
conditions.† Well-conducted observational cohort studies have
been used to support policy change at both national and
international levels and have the added benefit of assessing
feasibility as well as effectiveness of drugs and regimens‡,§
5 One potential benefit to carrying out operational research is that it
is an opportunity to strengthen country and program data
collection and routine monitoring systems, although additional
financial and human resources must be put toward this task. This
higher quality data can then be shared with local, national and
international bodies, including the WHO, to better inform future
policy decisions for the treatment of RR/MDR-TB at all levels
6 Countries—and the donors supporting them—should feel
comfortable utilizing regimens under operational research
conditions as part of health systems strengthening and closely
monitored implementation rather than separate, ‘stand alone’
research projects
* RESIST-TB. Clinical Trials Progress Report. http://www.resisttb.org/?page_
id¼1602.
† Cox HS, et al. The need to accelerate access to new drugs for multidrug-
resistant tuberculosis. Bull World Health Organ 2015; 93(7): 491–497.
‡ Khan F, et al. Effectiveness and safety of standardized shorter regimens for
multidrug-resistant tuberculosis: individual patient data and aggregate data
meta-analysis. Eur Respir J 2017; 50: 1700061.
§ World Health Organization. A 2016 review of available evidence on the use
of bedaquiline in the treatment of multidrug-resistant tuberculosis. WHO/
HTM/TB/2017.01. Geneva, Switzerland: WHO, 2017. http://www.who.int/tb/
publications/2017/GDGreport_Bedaquiline/en/
RR/MDR-TB ¼ rifampin-resistant/multidrug-resistant tuberculosis; SHORRT ¼
shorter, highly-effective, oral regimens for RR/MDR-TB therapy.
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ions on programmatic considerations for implementa-
tion of SHORRT therapy and all-oral regimens for FQ-
resistant RR/MDR-TB are reviewed in Table 5.
CONCLUSION
For the first time, the WHO has recommended an all-
oral therapy for the majority of people living with
RR/MDR-TB. AMK-based regimens should only be
used for people in need of ‘salvage’ or ‘rescue’
therapy. The WHO has recommended that people
for whom FQ-resistant TB has been ruled out or is
unlikely should receive a BDQ-containing 9–12-
month regimen. Given the concerns with the WHO
recommended 2016 shorter regimen, (with BDQ
given instead of the injectable agent) there are a
number of other ‘SHORRT’ regimens being used
under program conditions that, in the opinion of
these authors, could be considered for monitored
implementation by countries. People with likely or
documented FQ resistance will likely need longer, all-
oral regimens, although in some settings with
rigorous monitoring, the 6-month BPaL regimen or
endTB-Q regimen could be considered (See Table 6
Table 5 Programmatic considerations for all-oral treatment of
RR/MDR-TB
1 The top priority for TB programs is to halt the routine use of
injectable agents and begin offering all oral regimens for people
with RR/MDR-TB, unless they are in need of salvage therapy.
2 All countries need to urgently scale up laboratory testing to
detect resistance to rifampin and the fluoroquinolones with
further plans to develop and implement drug susceptibility
testing for BDQ, LZD, CFZ, and DLM
3 Countries will need to ensure they have adequate stocks of
newer drugs (BDQ and DLM) aligned with supply of companion
drugs (CFZ, LZD, levofloxacin, and possibly moxifloxacin)
4 There is a critical need for improved counseling on a number of
topics and social support—including a genuine approach to
‘patient-centered care’—for these regimens to be successful
5 As with any treatment for RR/MDR-TB, identifying and
managing adverse drug reactions during treatment are priority
activities (see Table 2). In addition to this, systems for reporting
serious, severe, and other adverse events of interest should be
developed or strengthened within the country to serve all
people with RR/MDR-TB regardless of their treatment regimen.
Active Drug Safety Monitoring and Management (aDSM)
should be done according to WHO principles* and national
guidelines: countries must make available the necessary human
and financial resources to implement quality aDSM
6 As part of roll out of all-oral regimens, countries need to
strengthen their monitoring and evaluation systems so local data
can be used to make decisions about optimizing treatment
7 While countries may consider rolling out some of the regimens
described above in selected locations or provinces, scale-up of
all-oral RR/MDR-TB treatment needs to take place on a national
level and implementation plans must be in place for equitable
and widespread access
8 Capacity building in the management of RR/MDR-TB is
paramount for a successful implementation of the newer
guidelines using the above agents.
* World Health Organization. Active drug-safety monitoring and manage-
ment: framework for implementation. Geneva, Switzerland: WHO, 2015.
RR/MDR-TB ¼ rifampin-resistant/multidrug-resistant tuberculosis; BDQ ¼
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for a summary of the authors’ recommendations). It is
essential that pregnant women, children, and people
living with HIV be prioritized for all-oral regimens.
There is no reason they—or other vulnerable popu-
lations—should be excluded. An exception to this is
PTM-containing regimens, until reproductive toxicity
studies are completed. Finally, programmatic issues
must be addressed to ensure rapid and equitable
access to these innovative treatments, but also to the
support people require to successfully complete the
regimens.
The WHO Guideline Development Group will
continue to meet and review additional evidence on
improving RR/MDRTB treatment. This is common
practice in the response to other epidemics and is a
welcome development that reflects the strengthened
science to support RR/MDR-TB management. In
addition to clear, unequivocal recommendations,
practice-based solutions are needed to help countries
decide on the optimal treatment strategies for their
settings. Countries should develop systems to rapidly
update their national guidelines and implementation
plans as better treatment data becomes available.
Strong, programmatic leadership and flexibility is
essential to ‘End TB’ and to ensure that a patient-
centered, human rights-based approach to RR/MDR-
TB is available to everyone affected by this disease.
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R É S U M É
Les diagnostics rapides, les nouveaux médicaments, les
médicaments recyclés et les protocoles plus courts ont
radicalement altéré le paysage du traitement des formes
de TB résistantes à la rifampicine et multirésistantes
(RR/MDR-TB). Il y a de nombreux essais cliniques en
cours visant à créer une solide base de données pour
guider le traitement de la RR/MDR-TB ; les études
d’observation ainsi que les données des programmes
ont contribué à faire progresser le domaine du
traitement. En décembre 2019, l’OMS a publié son
deuxième « Rapid Communication » relatif à la prise en
charge de la RR-TB ; l’OMS a réitéré sa
recommandation antérieure—que la majorité des
personnes atteintes de RR/MDR-TB reçoive des
protocoles de traitement uniquement oraux—et
autorise maintenant les protocoles spécifiques de plus
courte durée pour être utilisés également par les
programmes. De nombreux programmes TB ont
besoin de conseils cliniques quand ils veulent lancer
de tels protocoles dans le contexte spécifiques de leur
pays. Cette perspective fournit des expériences précoces
et des leçons apprises des Programmes Nationaux TB,
des partenaires, des cliniciens adultes et pédiatriques de
RR/MDR-TB et de la société civile pour optimiser le
traitement de la RR/MDR-TB, en utilisant des
protocoles oraux, plus courts, hautement efficaces
pour une majorité de personnes atteintes de RR/
MDR-TB.
R E S U M E N
Los métodos de diagnóstico rápido, los nuevos
fármacos, los medicamentos destinados a un nuevo
uso y los esquemas terapéuticos acortados han
modificado totalmente el panorama del tratamiento
de las formas de TB resistentes a rifampicina y
multirresistentes (RR/MDR-TB). En la actualidad,
están en curso múltiples ensayos clı́nicos encaminados
a obtener una evidencia sólida para orientar el
tratamiento de la RR/MDR-TB y, tanto los estudios
observacionales como los datos programáticos han
aportado avances en materia de tratamiento. En
diciembre del 2019, la OMS emitió su segunda
‘‘Comunicación rápida’’ sobre el manejo de la RR-TB;
la OMS reiteró su recomendación anterior de que la
mayorı́a de las personas con RR/MDR-TB deberı́an
recibir pautas de tratamiento de administración oral
exclusiva y ahora, permite además la administración de
tratamientos acortados especı́ficos en el marco
programático. Muchos programas de TB necesitan
asesoramiento clı́nico en el momento de desplegar estos
regı́menes en los entornos propios de su paı́s. La
perspectiva del presente artı́culo comunica las
experiencias iniciales y las enseñanzas aprendidas a
partir de los Programas Nacionales de TB, los
asociados, los médicos que se ocupan de la RR/MDR-
TB en los adultos y los niños y la sociedad civil, con el
propósito de optimizar el tratamiento de la RR/MDR-
TB con regı́menes acortados de administración oral
exclusiva y de gran eficacia, dirigidos a la mayorı́a de
las personas con estas formas de TB.
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